CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and
refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy. The
CAR enables the T cell to recognize and kill the leukemic cell through the recognition of
CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+
leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
The Pregene (ShenZhen) Biotechnology Company, Ltd.